Novo Nordisk to Lower US Insulin Prices

Novo Nordisk announced plans to lower prices for its pre-filled insulin pens and vials by 65-75% starting January 1, 2024. The news follows a similar move recently made by Lilly to cap most of its US insulin costs at $35/month (previous FENIX insight). Below, FENIX provides highlights and insights into Novo’s insulin price cuts, including an updated RAI and basal insulin pricing analysis.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.